Trust Signals
Written by the FormBlends Medical Team. Evidence graded by study type (human RCT, human clinical, animal, mechanistic). No affiliate relationships influence the safety assessments below. This page is a research reference, not medical advice. Hexarelin is not approved by the FDA for human therapeutic use.
Key Takeaways
- Hexarelin reliably elevates cortisol and prolactin acutely, a documented finding in human clinical studies, not just self-reports.
- Receptor desensitization (tachyphylaxis) is the most pharmacologically significant long-term risk and is measurable within days of continuous dosing in human research.
- Hexarelin binds both GHS-R1a and the CD36 scavenger receptor, making its hormonal side-effect profile broader than more selective secretagogues like ipamorelin.
- Water retention and fatigue are plausible class-effect concerns but lack specific hexarelin-controlled human trial data confirming frequency.
- Hexarelin is prohibited by WADA (Section S2) both in and out of competition, relevant to any athlete considering it.
Direct Answer: What Are Hexarelin Side Effects?
Hexarelin side effects documented in human studies include acute cortisol elevation, prolactin rise, and transient ACTH increases. Receptor desensitization with repeated dosing is the most clinically important long-term concern. Water retention, injection site reactions, fatigue, and increased appetite are commonly reported but supported mainly by user accounts and class-effect data rather than hexarelin-specific controlled trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Side Effects by Confidence Level
- The Mechanism Behind the Side Effects (With Numbers)
- Cortisol and Prolactin Elevation: What the Studies Show
- Receptor Desensitization: The Side Effect Most Pages Skip
- Cardiovascular Signals: Risk or Benefit?
- What Most Pages Get Wrong About Hexarelin Safety
- Honest Head-to-Head: Hexarelin vs. Ipamorelin vs. GHRP-2
- Label Literacy and Product Quality Gotchas
- Who Should Not Use Hexarelin
- FAQ
- Sources
Evidence Ledger: Hexarelin Side Effects by Confidence Level
| Side Effect | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Acute cortisol elevation | Human clinical (multiple studies, including Ghigo et al. and Arvat et al.) | Consistent increase, dose-related, transient | High |
| Acute prolactin rise | Human clinical (Arvat et al., published in peer-reviewed endocrinology journals) | Moderate increase, returns to baseline within hours | High |
| ACTH elevation | Human clinical | Consistent acute increase | High |
| GH-axis receptor desensitization | Human clinical (repeated-dose studies) | Blunted GH pulse with continuous dosing | Moderate to High |
| Water retention / edema | Class-effect (GH secretagogue mechanism) and user reports | Plausible increase | Low |
| Increased appetite / hunger | Mechanism (ghrelin mimetic, GHS-R1a activation) and user reports | Plausible increase | Low |
| Injection site redness / swelling | User reports, class effect | Mild, transient | Low (no controlled data) |
| Fatigue / somnolence | User reports | Inconsistent direction | Very Low |
| Cardioprotective effect (not a harm, but a biological signal) | Animal studies, limited human heart failure data | Positive in diseased tissue; unknown in healthy adults | Low (for healthy use) |
| Persistent HPA axis suppression | Theoretical; no controlled human data | Not demonstrated | Very Low |
The Mechanism Behind the Side Effects (With Numbers)
Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) that acts as a full agonist at the ghrelin receptor, formally GHS-R1a. GHS-R1a is a Gq-coupled GPCR. Activation triggers a phospholipase C cascade, raising intracellular calcium and driving pituitary somatotrophs to release GH in a pulsatile burst. This is the intended primary effect.
The side effects arise from two additional mechanisms that commodity pages routinely omit:
1. Hexarelin also binds CD36. CD36 is a scavenger receptor expressed on cardiac myocytes, adrenal cortex cells, and monocytes. Hexarelin's binding affinity for CD36 is structurally distinct from its GHS-R1a activity. It is this CD36 engagement, not GHS-R1a, that is believed to mediate the cortisol signal (via adrenal stimulation) and some of the cardiovascular effects observed in studies by Broglio and colleagues. This is why hexarelin's cortisol elevation persists even in subjects where GH response is blunted by somatostatin infusion.
2. GHS-R1a is constitutively active and widely distributed. The receptor is expressed in the hypothalamus, pituitary, hippocampus, heart, and adrenal gland. Stimulation outside the pituitary explains the breadth of the side-effect profile. The receptor also has roughly 50% constitutive activity at baseline, meaning hexarelin is not activating a silent receptor but amplifying an already-active one.
What this mechanism does NOT prove: These receptor-binding facts explain why side effects are biologically plausible. They do not establish the magnitude, clinical significance, or frequency of those side effects in real users at real research doses. Receptor binding data from in vitro studies does not translate directly to clinical harm thresholds.
Cortisol and Prolactin Elevation: What the Studies Show
The most rigorous human data on hexarelin's endocrine side effects comes from the Italian group led by Ghigo, Arvat, and Broglio, published in journals including the Journal of Clinical Endocrinology and Metabolism and Endocrinology in the 1990s and early 2000s. Their single-dose challenge studies (typically 2 mcg/kg IV in healthy adults) documented:
- A significant and consistent rise in plasma cortisol peaking within 30 to 60 minutes post-injection, above the GH-driven rise and attributable in part to direct adrenal and pituitary ACTH stimulation.
- A parallel and statistically significant prolactin increase of moderate magnitude, also peaking within 30 to 60 minutes and returning to baseline within 2 to 3 hours.
- Both cortisol and prolactin elevations were preserved even when GH secretion was pharmacologically suppressed, confirming the effects are not secondary to GH release but are direct.
The clinical implication: anyone with elevated baseline cortisol, active anxiety disorders, or conditions sensitive to prolactin (e.g., existing pituitary adenoma) faces a specific and evidence-supported endocrine risk that is not shared equally by other GH secretagogues.
Receptor Desensitization: The Side Effect Most Pages Skip
Tachyphylaxis is arguably the most practically important hexarelin-specific concern, and nearly every consumer-facing page omits it.
Repeated administration of hexarelin, particularly at high doses or with continuous scheduling, leads to measurable blunting of the GH response. In human studies by Arvat and colleagues examining repeated dosing regimens, the GH pulse amplitude declined with continued administration, a pattern less pronounced with GHRH-based peptides and substantially less pronounced with ipamorelin.
The mechanism: GHS-R1a undergoes beta-arrestin-mediated internalization after sustained agonist exposure. Because hexarelin is a full agonist (as opposed to a partial agonist), it drives receptor internalization more aggressively. GHRH, working through a different receptor (GHRHR), does not share this specific desensitization pathway, which is why GHRH plus GHRP combinations are sometimes preferred in clinical research protocols.
The practical consequence is that a user who doses hexarelin daily at high frequency may see a paradoxically blunted GH response within one to several weeks, defeating the purpose of use and potentially creating a transient functional deficit in endogenous GH pulsatility until the receptor population recovers.
Cardiovascular Signals: Risk or Benefit?
Hexarelin's cardiac pharmacology is genuinely unusual and deserves honest treatment. The CD36 binding described above mediates effects in cardiac myocytes that have been characterized as protective in animal models of ischemia-reperfusion injury and in small human studies of patients with ischemic cardiomyopathy (Broglio et al., published studies in the early 2000s). Hexarelin improved left ventricular function in some of these patient cohorts.
However, two important caveats apply:
First, the cardioprotective findings are from disease states. Extrapolating benefit to healthy adults is not warranted by the data. Second, CD36 is also expressed on atherosclerotic plaques and is involved in oxidized LDL uptake. The long-term consequences of repeated CD36 stimulation in healthy adults are not characterized in any controlled trial. This is not a demonstrated risk, but it is a genuine unknown that distinguishes hexarelin from peptides that lack CD36 activity.
What Most Pages Get Wrong About Hexarelin Peptide Side Effects
They conflate class effects with hexarelin-specific effects. Water retention and hunger are real concerns with GH secretagogues broadly. Attributing them specifically to hexarelin without hexarelin-specific trial data overstates what is actually known.
They ignore the CD36 receptor. Almost every consumer page describes hexarelin purely as a GHS-R1a agonist. The CD36 mechanism is why hexarelin's cortisol signal is unusually robust compared to GHRP-6 and ipamorelin at equivalent GH-releasing doses, and why its cardiac pharmacology is genuinely different.
They treat in vitro potency as clinical harm. Hexarelin is the most potent synthetic GH secretagogue by receptor binding assays. This does not automatically mean it has the worst side-effect profile at the doses used in research; dose selection matters more than potency ranking.
They omit the purity problem. Research-grade hexarelin from unregulated suppliers has no mandatory purity verification. A product labeled as hexarelin may contain bacterial endotoxins, truncated peptide fragments, or incorrect sequences. These contaminants, not the peptide itself, are a primary driver of adverse injection reactions in non-clinical settings.
Honest Head-to-Head: Hexarelin vs. Ipamorelin vs. GHRP-2
| Feature | Hexarelin | Ipamorelin | GHRP-2 |
|---|---|---|---|
| GH pulse magnitude (relative) | Very high | Moderate | High |
| Cortisol elevation (human data) | Consistent, documented | Minimal at standard doses | Moderate, documented |
| Prolactin elevation | Consistent, documented | Minimal | Moderate |
| Receptor desensitization risk | High (full agonist, rapid internalization) | Lower | Moderate |
| CD36 binding | Yes (unique among GHRPs) | No | No |
| Selectivity for GH axis | Lower | Higher | Moderate |
| Human clinical study volume | Moderate (multiple published studies) | Limited | Moderate |
| WADA prohibited | Yes (S2) | Yes (S2) | Yes (S2) |
| Where hexarelin loses | Cortisol, prolactin, desensitization profile | Ipamorelin wins on endocrine selectivity | Comparable or worse on cortisol |
If minimizing cortisol and prolactin perturbation is a priority, ipamorelin has a better documented side-effect margin than hexarelin at research doses. The trade-off is a smaller GH pulse. That is a real trade-off, not a hedge.
Label Literacy, Reconstitution, and Product Quality Gotchas
What to look for on a COA (Certificate of Analysis):
- Purity should be reported by HPLC, not just mass spectrometry alone. HPLC quantifies impurity peaks; MS only confirms molecular identity.
- Endotoxin testing (LAL assay) should be present. The absence of this test on a COA is a red flag for injectable research peptides.
- Molecular weight for hexarelin is 887.04 g/mol. A product with a significantly different MS value is not hexarelin.
Reconstitution and stability: Lyophilized hexarelin is stable at room temperature for short periods but should be stored frozen (around minus 20 degrees C) for longer storage. Once reconstituted in bacteriostatic water, the peptide is more susceptible to degradation. Peptide bond hydrolysis and oxidation of the tryptophan residue are the primary degradation pathways. Degraded product does not produce a characteristic smell or dramatic color change at low concentrations, which means visual inspection alone is insufficient quality control. A reconstituted solution that becomes cloudy or develops visible particles should be discarded due to contamination risk, not just potency concern.
Dosing reference (research context, not a clinical recommendation):
| Research Dose Range (published human studies) | Route | Context |
|---|---|---|
| 1 to 2 mcg/kg body weight | IV or subcutaneous | Single-dose endocrine challenge studies in published clinical research |
| Doses above 2 mcg/kg | Any | Cortisol and prolactin elevations become more pronounced; no additional GH benefit documented in dose-escalation data |
These figures describe what was used in published clinical research, not a prescription or protocol recommendation. Hexarelin is not approved for human therapeutic use.
Who Should Not Use Hexarelin
Hexarelin is not approved for human use and has no established safe dosing standard outside controlled research settings. The following groups face specific, evidence-supported elevated risks:
- Active malignancy: GH secretagogues can increase IGF-1, which promotes cell proliferation in GH-sensitive tumors.
- Elevated baseline cortisol or active HPA-axis disorders: The documented cortisol-elevating effect is a direct, additive risk.
- Prolactinoma or other prolactin-sensitive conditions: Prolactin elevation, even transient, is contraindicated.
- Active cardiovascular disease: CD36-mediated effects in diseased cardiac tissue are not well characterized for harm potential.
- Pregnant or breastfeeding individuals.
- Minors.
- Athletes subject to anti-doping rules: Hexarelin is a WADA S2 prohibited substance in and out of competition.
FAQ
What are the most common hexarelin side effects?
The most consistently documented side effects in human studies are cortisol elevation, prolactin rise, and transient ACTH increases, all measured acutely after single-dose administration. Water retention, fatigue, and hunger are commonly reported by users but lack controlled human trial data confirming their frequency.
Does hexarelin raise cortisol?
Yes. Multiple human studies have documented significant acute cortisol elevation following hexarelin administration. This is partly a GHS-R1a-independent effect mediated through the CD36 receptor and direct pituitary ACTH stimulation. The rise is dose-dependent and returns to baseline within hours.
Can hexarelin cause receptor desensitization?
Yes. Receptor tachyphylaxis is the most pharmacologically significant long-term concern with hexarelin. Unlike GHRH-based peptides, continuous or high-frequency hexarelin dosing produces measurable blunting of the GH pulse within days to weeks in human studies. Cycling protocols are used to mitigate this effect.
Does hexarelin affect prolactin levels?
Yes. Hexarelin acutely elevates prolactin, a finding documented in published human clinical studies. The magnitude is typically modest and transient, returning to baseline within a few hours. Chronic elevation causing clinical symptoms such as gynecomastia has not been documented in controlled studies at research doses.
Is hexarelin safe for the heart?
Evidence is mixed. Hexarelin binds the CD36 receptor expressed on cardiac tissue and has shown cardioprotective effects in animal and some human heart failure studies. However, the same receptor binding that mediates cardiac effects also contributes to cortisol elevation, so the cardiovascular risk-benefit profile is not fully characterized in healthy adults.
How does hexarelin compare to ipamorelin for side effects?
Ipamorelin is considered more selective: it elevates GH with minimal impact on cortisol or prolactin at standard doses, whereas hexarelin reliably raises both. For users prioritizing a cleaner hormonal profile, ipamorelin has a meaningfully better documented side-effect margin. Hexarelin's GH pulse is generally larger but less selective.
Does hexarelin cause water retention?
Water retention is commonly self-reported and is a known class effect of GH secretagogues due to IGF-1-mediated sodium and water reabsorption. Controlled data specific to hexarelin-induced fluid retention in humans is limited, so this is a plausible but low-evidence side effect.
What injection site reactions occur with hexarelin?
Subcutaneous injection site redness, mild swelling, and transient discomfort are reported by users. These are consistent with the class effects of subcutaneous peptide injection rather than hexarelin-specific toxicity. No necrosis or serious local reactions have been described in published human research.
Can hexarelin suppress the hypothalamic-pituitary axis long-term?
There is no published human data demonstrating persistent HPA or HPG axis suppression after hexarelin discontinuation at research doses. The desensitization seen with continuous dosing appears reversible in available studies. Long-term axis suppression remains a theoretical concern not yet characterized in controlled trials.
What does a degraded hexarelin product look like and is it dangerous?
Degraded hexarelin lyophilized powder may appear discolored (yellow or brown) or clump unusually. Reconstituted solution that appears cloudy or particulate after sterile water addition suggests contamination or degradation. Using degraded product risks reduced efficacy and, if contaminated, injection site infection or systemic inflammatory response.
Who should avoid hexarelin?
People with active malignancy, elevated baseline cortisol, prolactinoma, active cardiovascular disease, or those on glucocorticoid therapy should avoid hexarelin. Pregnant and breastfeeding individuals, minors, and anyone with a history of GH-sensitive tumors should not use it. It is not approved for human therapeutic use.
Is hexarelin banned in sport?
Yes. Hexarelin is listed on the WADA Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is prohibited both in and out of competition. Athletes subject to anti-doping rules must not use it.
Sources
- Ghigo E, Arvat E, Gianotti L, et al. "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man." Journal of Clinical Endocrinology and Metabolism. 1994;78(3):693-698.
- Arvat E, Gianotti L, Di Vito L, et al. "Modulation of growth hormone-releasing activity of hexarelin in man." Neuroendocrinology. 1995;61(1):51-56.
- Broglio F, Benso A, Castiglioni C, et al. "The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects." Journal of Clinical Endocrinology and Metabolism. 2003;88(4):1537-1542.
- Broglio F, Guarracino F, Benso A, et al. "Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during bypass surgery." European Journal of Pharmacology. 2002;448(2-3):193-200.
- Deghenghi R, Cananzi MM, Torsello A, et al. "GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats." Life Sciences. 1994;54(18):1321-1328.
- Muccioli G, Tschop M, Papotti M, et al. "Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity." European Journal of Pharmacology. 2002;440(2-3):235-254.
- Nakazato M, Murakami N, Date Y, et al. "A role for ghrelin in the central regulation of feeding." Nature. 2001;409(6817):194-198. (Background on GHS-R1a constitutive activity and receptor pharmacology).
- World Anti-Doping Agency. "Prohibited List 2024." WADA, Montreal. Available at: wada-ama.org. Accessed 2026.
- Howard AD, Feighner SD, Cully DF, et al. "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science. 1996;273(5277):974-977. (Primary GHS-R1a receptor characterization).
- Bodart V, Bouchard JF, McNicoll N, et al. "Identification and characterization of a new growth hormone-releasing peptide receptor in the heart." Circulation Research. 1999;85(9):796-802. (CD36 cardiac binding characterization for hexarelin).